Seagen

Seagen is a global biotechnology company that develops and commercializes innovative antibody-based therapies for the treatment of cancer. The company is known for its industry-leading antibody-drug conjugate (ADC) technology platform, which harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.

History[edit | edit source]

Seagen was founded in 1998 under the name Seattle Genetics. The company changed its name to Seagen in 2020 to reflect its growth and global presence. Since its inception, Seagen has been at the forefront of cancer research, developing a diverse portfolio of therapies and a robust pipeline of investigational drugs.

Antibody-Drug Conjugate (ADC) Technology[edit | edit source]

Seagen's Antibody-Drug Conjugate (ADC) technology is a targeted cancer therapy that delivers cytotoxic chemotherapy ("payload") to cancer cells via an antibody that specifically binds to a particular protein expressed on the cells. This approach is designed to spare non-targeted cells, thus reducing many of the toxic effects of traditional chemotherapy while enhancing antitumor activity.

Products[edit | edit source]

Seagen's product portfolio includes ADCETRIS (brentuximab vedotin), PADCEV (enfortumab vedotin-ejfv), and TUKYSA (tucatinib). These products have been approved by the U.S. Food and Drug Administration (FDA) and are used to treat various types of cancer, including Hodgkin lymphoma, urothelial cancer, and breast cancer.

Research and Development[edit | edit source]

Seagen's research and development efforts are focused on creating a new generation of targeted, empowered therapies designed to help patients with cancer. The company's pipeline includes several investigational drugs at various stages of clinical testing.